Your Messages Inbox
Most Viewed Abstracts
1. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 2. Omega-3 fatty acids for bipolar disorder 3. Is folic acid good for everyone 4. ACS Releases Guidelines for HPV Vaccination 5. Vitamin D - A review Free full text
Your Article Summary
See Latest ArticlesEffectiveness of adalimumab in treating patients with active psoriatic arthritis (PsA) and predictors of good clinical responses for arthritis, skin, and nail lesions
Annals of Rheumatic Diseases, 10/26/09
van den Bosch F et al. – Adalimumab was effective in patients with PsA. Lower impairment of physical function, greater pain, male sex, and no systemic treatment with glucocorticoids were factors that increased the chance of achieving good clinical response.
Methods- Prospective, 12-week, open-label, uncontrolled study
- Patients received adalimumab 40 mg every other week in addition to standard therapy
- 4 definitions of good clinical response: ≥ 50% improvement in American College of Rheumatology (ACR50) response criteria, good European League Against Rheumatism (EULAR) response,≥ 3-grade improvement in Physician's Global Assessment of psoriasis (PGA), and ≥ 50% improvement in the Nail Psoriasis Severity Index (NAPSI)
- 442 patients
- 94% completed 12 weeks of treatment
- Week 12, 74%, 51%, and 32% of the patients achieved ACR20, 50, and 70, respectively; 87% and 61% experienced a moderate and good EULAR response, respectively
- Percentage of patients with PGA "Clear/Almost Clear" increased from 34% (baseline) to 68%
- Mean NAPSI reduced by 44%
- No new safety signals detected
- Lower Health Assessment Questionnaire Disability Index score, greater pain assessment, male sex, and absence of systemic glucocorticoid therapy strongly associated with achievement of ACR50 and good EULAR response
- Greater CRP concentration and polyarthritis predicted ACR50, and noninvolvement of large joints predicted good EULAR response
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences
Vascular Health and Risk Management, 11/30/09
Efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne
International Journal of Women's Health, 11/30/09
Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified By National Cholesterol Education Program Risk Category
Metabolic Syndrome and Related Disorders, 11/30/09
Today in Orthopedic/Physical Med...keeping you current
Receive free subspecialty "5-minute updates" via email
Costs by industry and diagnosis among musculoskeletal claims in a state workers compensation system: 1999-2004
American Journal of Industrial Medicine, 11/30/09
Magnetic Resonance Imaging Assessment of Subchondral Bone and Soft Tissues in Knee Osteoarthritis
Rheumatic Disease Clinics of North America, 11/30/09
Treatment of osteoporosis: Recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity
Osteoporosis International, 11/30/09
Sponsor
Article Search
Sponsor
Sponsor